Brain Tumour Group,Genito-Urinary Cancers Group,Lung Cancer Group,News,Radiation Oncology Group,Soft Tissue and Bone Sarcoma Group,Uncategorized
Studies soon opened
11 Mar 2009
Studies opened since 01 January 2009
EORTC trial 08061
Phase II study of sunitinib (SU11248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a “sensitive” relapse.
EORTC trial 22055-08053
Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement
Studies in regulatory process
EORTC trial 22043-30041
Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in pathological stage pT3a-b R0-1/pT2R1 N0M0, Gleason score 5-10 prostatic carcinoma. A phase III study.
EORTC trial 26062-22061
A randomized phase III study of Temozolomide and short-course Radiation versus short-course Radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients
EORTC trial 30071
Double blind randomized phase II Trial in patients with advanced urothelial tract cancer (T3b,T4/N+/M+) of Gemcitabine and Cisplatin with Sorafenib or placebo.
EORTC trial 30072
A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
EORTC trial 62063
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023